ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Summary

An exploratory phase II trial of immune checkpoint inhibitors (ICIs, anti-PD-1/anti-PD-L1) as second-line treatment with advanced non-small cell lung cancer (NSCLC) who had long-term response to first-line immunotherapy (with or without chemotherapy). This study aims to evaluate efficacy and safety of ICI rechallenge in long-term responders to prior ICI. Furthermore, it seeks to identify biomarkers capable of predicting the efficacy of immunotherapy and prognosis.

Timeline

Start

2024-08-09

Primary completion

2027-01-10

Completion

2027-12-10

Drugs

Indications